- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Evolus Inc (EOLS)
Evolus Inc stock price live, this page displays NASDAQ EOLS stock exchange data. View the EOLS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Evolus Inc real time stock price chart below.
What Is the Evolus Inc Stock Price Today?
The Evolus Inc stock price today is 7.43.
What Is the Stock Symbol for Evolus Inc?
The stock symbol for Evolus Inc is ""EOLS.""
What Stock Exchange Does Evolus Inc Trade On?
Evolus Inc is listed and trades on the NASDAQ stock exchange.
Is Evolus Inc a Good Stock to Buy?
Determining whether Evolus Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the EOLS quote. (ISIN: US30052C1071)
What Is the Evolus Inc Stock Price Today?
The Evolus Inc stock price today is 7.43.
What Is the Stock Symbol for Evolus Inc?
The stock symbol for Evolus Inc is ""EOLS.""
What Stock Exchange Does Evolus Inc Trade On?
Evolus Inc is listed and trades on the NASDAQ stock exchange.
Is Evolus Inc a Good Stock to Buy?
Determining whether Evolus Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the EOLS quote. (ISIN: US30052C1071)
Fair Value
An estimate of a Evolus's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
7.34
7.95
52 wk Range
5.71
17.82
EOLS Scorecard
Full Analysis
3 analysts have revised their earnings downwards for the upcoming period
EOLS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Evolus's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
7.347.95
52 wk Range
5.7117.82
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
EOLS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Evolus's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Price Target
19.00
Upside
+155.72%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts do not anticipate the company will be profitable this year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell
Evolus Inc Company Profile
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Evolus Inc SWOT Analysis
Aesthetic Expansion | Evolus enters the hyaluronic acid dermal filler market with FDA-approved Evolysse, potentially increasing its addressable market by 78% to $6 billion |
Financial Milestones | Explore Evolus's journey to profitability, with Q3 2024 revenue of $61 million and ambitious targets of $700 million revenue by 2028 |
Market Dynamics | Delve into the "Ozempic effect" driving filler demand and how Evolus's cold cross-linking technology positions it against established competitors |
Growth Trajectory | Analysts project $16-$27 price targets, with fillers expected to contribute 8-10% of 2025 revenue, signaling potential for significant market expansion |
Evolus Inc Earnings Call Summary for Q2/2025
- Evolus Q2 2025 EPS of -$0.27 missed forecast of -$0.10; revenue of $69.4M fell short of $82.18M expectation, causing 2.2% stock drop
- Company maintained 14% neurotoxin market share; implemented $25M cost cuts to achieve profitability by 2026
- Full-year 2025 revenue guidance reaffirmed at $295-$315M; targeting positive operating income by Q4 2025
- CEO emphasized intact business fundamentals and efficient cost structure; $700M revenue target by 2028 with 20% non-GAAP operating margin
- Analysts maintain optimistic price targets ($20-$27) despite current challenges; company cites strong Evolisse launch reception
Last Updated: 05/08/2025, 22:54
Read Full TranscriptCompare EOLS to Peers and Sector
Metrics to compare | EOLS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipEOLSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −7.8x | 6.0x | −0.6x | |
PEG Ratio | 0.98 | 0.17 | 0.00 | |
Price/Book | −25.8x | 2.0x | 2.6x | |
Price / LTM Sales | 1.7x | 1.7x | 3.3x | |
Upside (Analyst Target) | 165.3% | 33.8% | 39.0% | |
Fair Value Upside | Unlock | 23.3% | 4.9% | Unlock |
Analyst Ratings
6 Buy
1 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 19.00
(+155.72% Upside)
Earnings
Latest Release
Aug 05, 2025
EPS / Forecast
-0.27 / -0.10
Revenue / Forecast
69.40M / 82.18M
People Also Watch
FAQ
What Stock Exchange Does Evolus Trade On?
Evolus is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Evolus?
The stock symbol for Evolus is "EOLS."
What Is the Evolus Market Cap?
As of today, Evolus market cap is 480.61M.
What Is Evolus's Earnings Per Share (TTM)?
The Evolus EPS (TTM) is -0.97.
When Is the Next Evolus Earnings Date?
Evolus will release its next earnings report on 10 Nov 2025.
From a Technical Analysis Perspective, Is EOLS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Evolus Stock Split?
Evolus has split 0 times.
How Many Employees Does Evolus Have?
Evolus has 394 employees.
What is the current trading status of Evolus (EOLS)?
As of 26 Aug 2025, Evolus (EOLS) is trading at a price of 7.43, with a previous close of 7.43. The stock has fluctuated within a day range of 7.34 to 7.95, while its 52-week range spans from 5.71 to 17.82.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.